Keith Cooper
Overview
Explore the profile of Keith Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buchanan R, Reinson T, Bilson J, Woodland H, Nwoguh C, Cooper K, et al.
BMJ Open
. 2025 Mar;
15(3):e088043.
PMID: 40050060
Introduction: Hepatocellular carcinoma (HCC) is expected to become the third most common cause of cancer death worldwide by 2030. The increase in HCC is in large part due to the...
2.
West C, Tiwari A, Salem Y, Woyton M, Alford N, Roy S, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796738
Conventional pelvic exenteration (PE) comprises the removal of all or most central pelvic organs and is established in clinical practise. Previously, tumours involving bone or lateral sidewall structures were deemed...
3.
Cooper K, Maund E, Takahashi M, Shepherd J
Pharmacoeconomics
. 2024 Aug;
42(11):1177-1179.
PMID: 39120843
No abstract available.
4.
Bolam S, Cooper K, Downie A
Ecol Appl
. 2023 Jul;
33(7):e2905.
PMID: 37421319
Escalating societal demands placed on the seabed mean there has never been such a pressing need to align our understanding of the relationship between the physical impact of anthropogenic activities...
5.
Nair R, Halford Z, Towers W, Breite L, Cooper K, Shah S
Curr Oncol Rep
. 2023 Feb;
25(4):379-386.
PMID: 36808556
Purpose Of Review: There is a paucity of evidence for managing perioperative anticoagulation in patients with cancer. This review aims to provide clinicians who provide care for patients with cancer...
6.
Molodynski A, Puntis S, Mcallister E, Wheeler H, Cooper K
BJPsych Bull
. 2020 Dec;
46(3):193.
PMID: 33323156
No abstract available.
7.
Molodynski A, Puntis S, Mcallister E, Wheeler H, Cooper K
BJPsych Bull
. 2020 Jan;
44(6):231-232.
PMID: 31964448
Recent years have seen a surge in interest in mental healthcare and some reduction in stigma. Partly as a result of this, alongside a growing population and higher levels of...
8.
The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective
Buchanan R, Cooper K, Grellier L, Khakoo S, Parkes J
J Viral Hepat
. 2019 Sep;
27(1):36-44.
PMID: 31520434
New antiviral drugs with high efficacy mean the hepatitis C virus (HCV) can now be eliminated. To achieve this, it is necessary to identify undiagnosed cases of HCV. However, the...
9.
Picot J, Kalita N, Gaisford W, Harris P, Onyimadu O, Cooper K
Pharmacoeconomics
. 2018 Oct;
37(6):753-762.
PMID: 30328052
Clinical and cost-effectiveness evidence on fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer was submitted to the single technology appraisal process of the National Institute for Health...
10.
Cooper K, Frampton G, Harris P, Rose M, Chorozoglou M, Pickett K
Pharmacoeconomics
. 2018 Mar;
36(5):545-553.
PMID: 29582406
As part of the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) process, the manufacturer of reslizumab (Teva) submitted evidence for its clinical and cost effectiveness...